-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, news came from the industry that Shanghai Bendao Gene Technology Co.
, Ltd.
(hereinafter referred to as Bendao Gene), a gene therapy development company with original delivery technology, completed a round A financing of 60 million yuan, led by Huakong Fund, Enran Venture Capital, Longmen Capital, ETP Fund, Inno Angel Fund and many other institutions followed in the investment.
This round of financing funds will be used for preclinical and clinical development of multiple products, laboratory and team building, etc.
According to the information on the official website of this guide gene, the company was established in 2018, focusing on in vivo gene editing and in vitro transgene therapy development.
As we all know, gene therapy has become the third revolutionary therapy after chemical drugs and antibody drugs with its unique advantage of "one-shot cure", and has made a series of significant progress in recent years.
The development of the technology platform of this guide gene is precisely to address this challenge.
Dr.
According to the information on the official website of the guide gene, based on its technology platform, the guide gene has established a research pipeline covering diseases such as diabetic macular degeneration, wet age-related macular degeneration (wAMD), and hematopoietic system genetic diseases.
Source: Bendao Gene's official website
Mr.
He also said that in the future, he will support the development of this guide gene for a long time, jointly promote the company's original delivery technology and products, and help gene therapy achieve a leap from "1 to 100", so that there will be more drugs that are difficult to cure and no drugs in the future.